Bristol-Myers Boosts Full-Year Forecast, Names CEO

Drug maker Bristol-Myers Squibb said Thursday its first-quarter earnings and revenue fell from the same quarter last year, due to a decline in global pharmaceutical sales, but the company raised its full-year profit outlook.

The company also said interim CEO James M. Cornelius has been elected permanent chief executive.

Bristol-Myers Squibb reported net earnings of $690 million, or 35 cents a share, for the first quarter, down from net profit of $714 million, or 36 cents a share, in the same quarter a year ago.

Revenues fell to $4.5 billion from $4.7 billion, in the year-ago period. Sales of cardiovascular drug Plavix fell 6% to $1.9 billion because of generic competition.

Excluding one-time items, Bristol-Myers said it earned 38 cents a share in the first quarter, up from 32 cents a share in the year-ago period.

Analysts surveyed by Thomson Financial predicted earnings of 23 cents a share on revenues of $4.28 billion.

For the full year, the company boosted its forecast for net income to $1.24 to $1.34 a share from $1.12 to $1.22 a share. Excluding one-time items, Bristol-Myers predicts a profit of $1.30 to $.140 a share, up from earlier guidance of $1.20 to $1.30 a share.

Contact U.S. News


    Get the best of CNBC in your inbox

    › Learn More

Don't Miss

U.S. Video

  • Mad Money's Jim Cramer breaks down the theme of stealth technology stocks. Cramer says companies that are using proprietary technology to invent entirely new markets and then dominate those markets, fall under that category.

  • Mad Money host Jim Cramer knows it can be difficult to stick with a stock that is going lower but says if you've done the homework, and the story isn't wildly off the rails, then stay long.

  • Mad Money host Jim Cramer, outlines the most common emotionally driven investor mistakes and expresses why it is important to not let skepticism run away with you.